Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + ribavirin + telaprevir
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a triple therapy combination used for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. The regimen combines peginterferon alfa-2b (a synthetic version of substances normally produced in the body to fight infection), ribavirin (an antiviral medication), and telaprevir (a direct-acting antiviral HCV NS3/4A protease inhibitor). This combination demonstrated superior efficacy compared to the standard dual therapy of peginterferon and ribavirin alone, achieving higher sustained virological response (SVR) rates within shorter treatment durations.
- Brand names
- PEG-Intron/Peg Intron RP
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa-2b + ribavirin + telaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + ribavirin + telaprevir.